(Q37012017)

17 August 2017

1 reference

title

Pharmacogenetics of the PPAR genes and cardiovascular disease (English)

1 reference

17 August 2017

main subject

cardiovascular disease

1 reference

Sharon Cresci

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1581-1595

1 reference

Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Molecular characterisation of six alternatively spliced variants and a novel promoter in human peroxisome proliferator-activated receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPAR delta: an uncompletely known nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Nuclear receptor signaling and cardiac energetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPAR delta: a dagger in the heart of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Nuclear receptors and their relevance to diseases related to lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Digging deep into the pockets of orphan nuclear receptors: insights from structural studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptors, coactivators, and downstream targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Roles of PPARs on regulating myocardial energy and lipid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Differential effect of PPARgamma2 variants in the development of type 2 diabetes between native Japanese and Japanese Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The association of Pro12Ala polymorphism in PPARgamma2 with lower carotid artery IMT in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPARgamma, the ultimate thrifty gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Novel insulin sensitizers: pharmacogenomic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

PPARgamma agonists: safety issues in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the Data From an Epidemiological Study on the Insulin Resi

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Sequence variation in PPARG may underlie differential response to troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor γ Associated With Carotid Atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.11.1581

10.2217/14622416.8.11.1581

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference